Barings LLC continued to hold its stake in Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,300 shares of the medical equipment provider’s stock at the close of the second quarter. Barings LLC’s holdings in Hologic were worth $864,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Commonwealth Bank of Australia lifted its holdings in Hologic by 31.0% in the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after purchasing an additional 600 shares in the last quarter. Miles Capital Inc. acquired a new stake in shares of Hologic in the 1st quarter worth $206,000. Beck Mack & Oliver LLC acquired a new stake in shares of Hologic in the 2nd quarter worth $209,000. Notis McConarty Edward acquired a new stake in shares of Hologic in the 2nd quarter worth $213,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Hologic in the 2nd quarter worth $213,000. Institutional investors own 96.38% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.com-unik.info/2017/10/13/barings-llc-has-864000-holdings-in-hologic-inc-holx.html.
In related news, VP Karleen Marie Oberton sold 4,704 shares of the stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $45.19, for a total transaction of $212,573.76. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Lawrence M. Levy sold 7,139 shares of the stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $39.04, for a total value of $278,706.56. The disclosure for this sale can be found here. Insiders have sold 35,479 shares of company stock worth $1,388,236 over the last quarter. 0.79% of the stock is currently owned by company insiders.
Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The firm had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. During the same period in the prior year, the business posted $0.51 earnings per share. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year.
A number of analysts have issued reports on the company. Jefferies Group LLC reaffirmed a “buy” rating and issued a $44.00 target price (down from $49.00) on shares of Hologic in a research note on Tuesday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $45.00 target price (down from $48.00) on shares of Hologic in a research note on Monday. Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 target price on shares of Hologic in a research note on Monday, October 2nd. Finally, Royal Bank Of Canada reaffirmed a “hold” rating and issued a $42.00 target price on shares of Hologic in a research note on Friday, September 22nd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $47.77.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
What are top analysts saying about Hologic Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic Inc. and related companies.